The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
Authors:
- 9 May 2011
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (3) , 380-386
Abstract
Between 1982 and 2009 a total of 92 patients with myelofibrosis (MF) in chronic phase underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) was given to 40 patients, and reduced intensity conditioning (RIC) was used in 52 patients. The mean age in the two groups at transplantation was 46±12 and 55±8 years, respectively (PP=0.003). Among the RIC patients, the survival was significantly (P=0.003) better for the patients with age P=0.125). Patients treated with RIC experienced significantly less aGVHD compared with patients treated with MAC (PP=0.038, when age adjustment was made). Twenty-one percent of the patients in the RIC group were given donor lymphocyte infusion because of incomplete donor chimerism, compared with none of the MAC-treated patients (P<0.002). Nine percent of the patients needed a second transplant because of graft failure, progressive disease or transformation to AML, with no significant difference between the groups. Our conclusions are (1) allo-SCT performed with RIC gives a better survival compared with MAC. (2) age over 60 years is strongly related to a worse outcome and (3) patients with higher Lille score had a shorter survival.Keywords
This publication has 20 references indexed in Scilit:
- A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosisBone Marrow Transplantation, 2009
- 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosisEuropean Journal of Haematology, 2008
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelBlood, 2007
- Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimensBritish Journal of Haematology, 2006
- Clinicopathological Criteria for Differential Diagnosis of Thrombocythemias in Various Myeloproliferative DisordersSeminars in Thrombosis and Hemostasis, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 casesBlood, 2005
- Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaThe American Journal of Medicine, 2004
- Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99Journal of Internal Medicine, 2004
- Allogeneic hematopoietic stem cell transplantation for myelofibrosisBlood, 2003